S

Santen

Develops medicines and devices for eye health

Global Safety Vigilance Risk Management Lead

Full-TimeUpdated on 10/15/2026
No salary listed
Senior
Bachelor's
Singapore
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • More than five years of experience in drug safety activities, including pharmacovigilance, medical affairs, medical science liaison, regulatory affairs, research and development, clinical development, or non-clinical research in pharmaceutical companies.
  • A bachelor's degree in Life Science or a related field.
  • Experience in cross-functional and regional projects, such as research and development projects.
  • Experience in risk management for medicinal products.
  • Knowledge of the product development process, including preparation of New Drug Application/Marketing Authorization Application dossiers.
  • Ability to work independently or in a small Pharmacovigilance unit within a global Safety Vigilance structure.
  • Strong verbal and written communication skills in English.
  • Ability to participate effectively in multidisciplinary teams.
  • Solid decision-making, partnering, team-orientation, and influencing skills.
  • Computer skills, including Microsoft Office and Word.
Responsibilities
  • Consider the impact on subject and patient safety and product value maximization from development through the post-marketing stage.
  • Act as Product Safety Lead for risk-management activities involving investigational and post-marketing products.
  • Prepare signal assessment documents.
  • Create action plans to mitigate and manage product risks.
  • Develop and maintain product Core Risk Management Plans and Company Core Safety Information.
  • Prepare aggregate safety reports such as Periodic Safety Update Reports.
  • Develop clinical-trial documents such as Development Safety Update Reports and safety management plans, and conduct periodic risk monitoring of investigational products.
  • Lead preparation of safety-related documents for New Drug Application/Marketing Authorization Application dossiers in collaboration with Safety Vigilance members and stakeholders; understand requirements in the filing country, dossier submissions, and communications with health authorities in other regions and countries referenced by the filing country.
  • Contribute scientific and strategic input to research and development projects as a Safety Vigilance representative.
  • Support global Safety Vigilance activities and projects as directed by the Head of Medical Evaluation and Risk Management.
Desired Qualifications
  • A pharmacist qualification.

About the company

S

Santen

View
Website

Santen researches, develops, manufactures and markets medicines and medical devices for eye care. Its portfolio includes prescription treatments for glaucoma, dry eye, allergies and other eye conditions, alongside nonprescription products and surgical devices. The company combines laboratory research and clinical development with formulation, quality control and manufacturing to bring products to healthcare markets. It earns revenue from pharmaceutical and device sales, working through regional subsidiaries and commercial partners to supply healthcare professionals, pharmacies and other customers. Founded in 1890, Santen is headquartered in Osaka, Japan, and sells products internationally.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

N/A

Founded

1890

Get referred to Santen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Santen's Western Europe Quality Lead role offers a €112,100 to €154,130 base salary, depending on experience and location.
  • Santen launched Rhopressa eye drops in Japan in August 2026, adding a commercial glaucoma product.
  • Santen's Shiga production center supplies eye-care products to Japan, Europe, Korea and other Asian markets.

What critics are saying

  • Santen's revenue fell 2.8% to ¥291.6 billion in the year ended March 2026, despite higher operating profit.
  • Santen's France Medical Science Liaison role requires up to 70% domestic travel, plus occasional international travel.
  • Santen's Amsterdam quality internship requires continuous student enrollment and at least five months of full-time work.

What makes Santen unique

  • Santen concentrates basic research, nonclinical studies and formulation research at its Nara Research and Development Center.
  • Santen's Dropaid delivery aids are designed specifically for its single-dose and preservative-free multidose eye-drop containers.
  • Santen's Preserflo MicroShunt is a CE-marked surgical implant designed to drain aqueous fluid from the eye.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Company News

JapanNews24
Aug 5th, 2026
Santen joins Global Summit for Eye Health as High Impact Partner - japan Industry News.

Santen joins Global Summit for Eye Health as High Impact Partner - japan Industry News. August 5, 2026 Discover more Law Enforcement Machine Learning & Artificial Intelligence Japanese Cuisine Santen Pharmaceutical Co., Ltd. introduced its participation as a High Impact Partner within the inaugural Global Summit for Eye Health, set to happen on November 2, 2026, in Antigua & Barbuda. The summit, organized by the International Agency for the Prevention of Blindness (IAPB) in collaboration with the World Health Organization (WHO), goals to handle the worldwide problem of imaginative and prescient impairment. The occasion will see the launch of the Global Eye Health Compact, a brand new framework designed to speed up progress in eye well being by means of measurable commitments from governments and organizations. Santen's position as a High Impact Partner entails shaping the compact and unveiling its world eye well being dedication through the summit. Rie Nakajima, Director of the Board and Chief Operating Officer of Santen Global, emphasised the significance of collaborative efforts in tackling imaginative and prescient impairment. Nakajima said, "No single organization can solve the growing burden of vision impairment alone. By working alongside governments, healthcare professionals, patient organizations, and global partners, we can help strengthen eye health systems, improve access to quality eye care, and deliver lasting benefits for people around the world." Santen's involvement on the summit builds on its longstanding collaboration with IAPB and different companions within the eye well being neighborhood. The firm has been energetic in initiatives to advance childhood myopia and promote wholesome eye well being habits for kids. Peter Holland, CEO of IAPB, welcomed Santen's participation, noting that collaboration is important to delivering eye care providers at scale and velocity. Holland commented, "Only by working together like this can we deliver eye care services at scale and speed to end avoidable or treatable sight loss." The summit will convey collectively heads of presidency, ministers, worldwide organizations, civil society, and private-sector leaders to set concrete commitments for strengthening eye well being providers worldwide. The aim is to align world motion and speed up progress to succeed in over 1 billion folks dwelling with avoidable sight loss. Santen's participation within the summit underscores its dedication to advancing eye well being and addressing one of many world's most ignored public well being challenges. With greater than 135 years of dedication to eye well being, the corporate goals to contribute considerably to the conclusion of improved world eye well being outcomes. Discover more Demographics Journalism & News Industry Crime & Justice

Santen Pharmaceutical
Aug 5th, 2026
Santen joins inaugural Global Summit for Eye Health as high-impact Partner.

Santen joins inaugural Global Summit for Eye Health as high-impact Partner. Osaka, Japan - 5 August 2026 - Santen Pharmaceutical Co., Ltd. today announced it will join the inaugural Global Summit for Eye Health as a High Impact Partner, marking another step in the company's long-standing commitment to advancing eye health worldwide. Organized by the International Agency for the Prevention of Blindness (IAPB) in technical collaboration with the World Health Organization (WHO), the Summit will bring together heads of government, ministers, international organizations, civil society, and private-sector leaders in Antigua & Barbuda, a Caribbean island nation on 2 November 2026. Together, they will launch the Global Eye Health Compact, a new global framework designed to accelerate progress through measurable commitments from governments and organizations. As a High Impact Partner, Santen helps shape the Global Eye Health Compact and, at the Summit, will unveil its global eye health commitment, outlining how the company will contribute to improving eye health over the coming years. Despite being essential to education, employment, independence, and healthy aging, eye health remains one of the world's most overlooked public health challenges. More than one billion people worldwide continue to live with avoidable vision impairment[*1], highlighting a critical gap between available solutions and access to care. Addressing this challenge requires coordinated action across prevention, early diagnosis, treatment, and public policy. Rie Nakajima, Director of the Board, Chief Operating Officer of Santen Global, commented: "No single organization can solve the growing burden of vision impairment alone. By working alongside governments, healthcare professionals, patient organizations, and global partners, we can help strengthen eye health systems, improve access to quality eye care, and deliver lasting benefits for people around the world. With more than 135 years of dedication to eye health, Santen is proud to join this global coalition." Santen's participation builds on its longstanding collaboration with IAPB and partners across the eye health community to strengthen policy, raise awareness, and promote early action, including initiatives to advance childhood myopia and encourage healthy eye health habits for children. Peter Holland, CEO, IAPB, commented: "We welcome Santen's participation in the first Global Summit for Eye Health and look forward to continuing our collaboration to strengthen eye health policies and improve outcomes for over 1 billion people who experience vision problems worldwide. Only by working together like this can we deliver eye care services at scale and speed to end avoidable or treatable sight loss." About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" - Exploring the secrets and mechanisms of nature in order to contribute to people's health - Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit https://www.santen.com/en. About the Global Summit of Eye Health On 2 November, Antigua and Barbuda will host the world's first Global Summit for Eye Health - the moment when governments, partners and global leaders unite for the first time to ensure everyone, everywhere can access the eye care they need. At the Summit, countries will set out concrete commitments to strengthen eye health services worldwide, aligning global action and accelerating progress to help reach over 1 billion people living with avoidable sight-loss. For more information, please visit Global Summit for Eye Health - Making the world see the value of vision About IAPB IAPB is the overarching alliance for the global eye health sector, with more than 250 member organisations in over 100 countries working together for a world where everyone has universal access to eye care. IAPB believes in a world in which no one is needlessly visually impaired, where everyone has access to the best possible standard of eye health; and where those with irreparable sight loss achieve their full potential. Its key priorities are global advocacy, campaigning on a different level, sharing knowledge, and strengthening the network: www.iapb.org. Partnership Transparency Statement Santen supports the activities described in this initiative through collaboration with IAPB. The organizations maintain independent governance and decision-making. The views expressed by IAPB are its own and do not necessarily reflect those of Santen. For media inquiries: Santen Pharmaceutical Co., Ltd. Corporate Communications Email: [email protected] This press release has been published in Japanese, Simplified Chinese and English languages and in the event of any inconsistency, the English version shall prevail.

Santen Pharmaceutical
Apr 17th, 2026
Santen China signs exclusive distribution and promotion agreement for five marketed Glaucoma Eyedrops products in the Chinese Mainland.

Santen China signs exclusive distribution and promotion agreement for five marketed Glaucoma Eyedrops products in the Chinese Mainland. April 17, 2026 - Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced today that Santen China has entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eyedrops in the Chinese Mainland. Under the agreement, Santen China will receive exclusive distribution rights and conduct promotional activities in the Chinese Mainland for Glaucoma Eyedrops Alphagan(R), AlphaganP(R), Lumigan(R), Ganfort(R) and Combigan(R). A pillar of AbbVie's glaucoma eyedrop product portfolio, the brimonidine tartrate ophthalmic solution (Alphagan(R) and AlphaganP(R) features a dual intraocular pressure (IOP)-lowering effect that suppresses aqueous humor production and promotes aqueous humor outflow via the uveoscleral pathway; it is recommended as one of the first-line treatments under Asia-Pacific Glaucoma Society guidelines.[1] These products will synergize with existing Santen prostaglandin-related products while creating a complementary, multi-MoA (Mechanism of Action) glaucoma portfolio and strengthening the Company's business foundation in the China market. Glaucoma is a disease in which the optic nerve is damaged by increased IOP, causing progressive visual field loss; if not treated appropriately, it can lead to blindness.[2,3] As of 2020, the number of patients with primary glaucoma worldwide exceeded 76 million, and this number is expected to exceed 100 million by 2040.[4] The number of glaucoma patients in China numbered more than 21.8 million, leading to 5.67 million cases of blindness as of 2020.[2] By fully leveraging its proven strong commercial presence in China's glaucoma market, Santen will capitalize on this agreement with AbbVie to unleash the growth potential of the glaucoma products. While focusing on addressing clinical challenges in glaucoma treatment, Santen is committed to providing eye care professionals with new therapeutic strategies and approaches, empowering them to elevate the standard of glaucoma treatment in China, and ultimately benefit millions of patients. References * Asia-Pacific Glaucoma Guidelines, 4th Edition. 2024 * Chinese Glaucoma Guideline (2020) [J]. Chinese Journal of Ophthalmology, 2020, 56(8): 573-586. * Weinreb RN, et al. JAMA. 2014;311(18):1901-1911. * Tham YC, et al. Ophthalmology. 2014;121(11):2081-2090. About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" - Exploring the secrets and mechanisms of nature in order to contribute to people's health - Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit https://www.santen.com/en. About AbbVie Founded in 2013, AbbVie is a top 5 research-based global biopharmaceutical company headquartered in North Chicago, Illinois, the USA. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Santen Pharmaceutical Co. strive to have a remarkable impact on people's lives across several key therapeutic areas - immunology, oncology, neuroscience, and eye care - and products and services in its Allergan Aesthetics portfolio. Contact Corporate Communications Santen Pharmaceutical Co., Ltd. E-mail: [email protected] This press release has been published in Japanese, Simplified Chinese and English languages and in the event of any inconsistency, the English version shall prevail.

AD HOC NEWS
Apr 3rd, 2026
Rohto Pharmaceutical stock: A stable leader in Japan's eye care and OTC market with global expansion potential.

Rohto Pharmaceutical stock: A stable leader in Japan's eye care and OTC market with global expansion potential. 03.04.2026 - 09:39:13 | ad-hoc-news.de Rohto Pharmaceutical Co., Ltd. (ISIN: JP3982400008) stands as a key player in over-the-counter pharmaceuticals and cosmetics, particularly known for eye care products. North American investors may find value in its steady domestic performance and growing international footprint amid rising global demand for self-care health solutions. Rohto Pharmaceutical Co., Ltd. operates as a prominent Japanese firm focused on over-the-counter drugs, cosmetics, and functional foods. The company holds a strong position in eye drops, skincare, and medicated products, serving consumers seeking quick-relief solutions for everyday health needs. Listed on the Tokyo Stock Exchange under ticker 4527 with ISIN JP3982400008, Rohto trades in Japanese yen. Its business model emphasizes research-driven innovation combined with efficient manufacturing and wide distribution networks. As of: 03.04.2026 By Elena Marcus, Senior Financial Editor at NorthStar Market Insights: Rohto Pharmaceutical exemplifies disciplined growth in the consumer health sector, balancing tradition with targeted global outreach. Core business and product portfolio. Official source All current information on Rohto Pharmaceutical directly from the company's official website. Rohto's flagship products include the Z! series of eye drops, which target dryness, fatigue, and allergies. These items dominate Japan's market due to their fast-acting formulas and trusted brand reputation built over decades. The company also offers skincare lines like Melano CC vitamin C serum and Obagi, which has gained traction internationally. Functional foods and medicated shampoos round out the portfolio, addressing consumer needs in personal care. Manufacturing occurs primarily in Japan with facilities optimized for high-volume production. Rohto invests in R&D to develop proprietary ingredients, ensuring product differentiation in competitive categories. Sales channels span pharmacies, convenience stores, and e-commerce platforms. This multi-channel approach supports consistent revenue streams even during economic fluctuations. Market position and competitive landscape. Sentiment and reactions In Japan, Rohto competes with firms like Lion Corporation and Santen Pharmaceutical in the eye care segment. Its market share remains robust, supported by brand loyalty and frequent product refreshes. Globally, Rohto expands through subsidiaries in Asia, Europe, and North America. The acquisition of interests in brands like Obagi positions it against larger players such as L'Oréal and Procter & Gamble in cosmetics. Rohto differentiates via science-backed formulations. For instance, its eye drops incorporate menthol and vitamins, offering relief not matched by generic alternatives. Distribution strength in Southeast Asia bolsters growth. Partnerships with local retailers enhance accessibility in high-population markets like Indonesia and Vietnam. The company's focus on OTC products avoids prescription drug complexities. This regulatory advantage allows quicker market entry and lower compliance costs. Financial health and performance drivers. Rohto maintains steady profitability through cost controls and premium pricing. Its balance sheet reflects low debt levels, providing flexibility for investments. Revenue derives mostly from Japan, with international sales growing steadily. Export of eye care and skincare products drives overseas expansion without heavy localization costs. Operating margins benefit from economies of scale in production. Efficient supply chains minimize disruptions, even amid global logistics challenges. Dividend policy supports shareholder returns. Consistent payouts appeal to income-focused investors seeking stability in volatile markets. R&D expenditure focuses on consumer trends like anti-aging and digital eye strain. These align with demographic shifts in aging populations across Asia. Strategic initiatives and growth catalysts. Rohto pursues overseas expansion via joint ventures and acquisitions. Entry into the U.S. market through Obagi leverages demand for premium skincare. Digital transformation enhances e-commerce capabilities. Online sales platforms cater to younger consumers preferring direct-to-consumer models. Sustainability efforts include eco-friendly packaging. This resonates with global trends toward responsible consumption, potentially opening premium segments. Innovation pipelines feature new eye care solutions for screen users. With rising remote work, such products address a persistent need. Partnerships with tech firms explore wearable health devices. Integration of pharma with tech could create future revenue streams. Relevance for North American investors. Further developments, updates, and context on the stock can be explored quickly through the linked overview pages. North American investors gain exposure to Japan's consumer health boom via Rohto. The stock offers diversification into Asia's stable pharma sector. U.S. presence through Obagi provides a foothold in the $100 billion skincare market. Growth here could accelerate returns for international holders. Currency dynamics play a role; a weaker yen enhances repatriated earnings. Hedging strategies mitigate forex risks for global portfolios. Rohto's defensive qualities suit conservative allocations. Demand for OTC products persists across economic cycles, unlike cyclical sectors. Accessibility via OTC markets or ADRs simplifies investment. Monitoring U.S. sales milestones offers clear catalysts for value appreciation. Risks and key questions for investors. Regulatory changes in Japan could impact OTC approvals. Stricter guidelines on ingredients pose compliance challenges. Competition intensifies from domestic and global rivals. Maintaining market share requires ongoing innovation investment. Currency fluctuations affect reported results. A strengthening yen might pressure margins for export-focused growth. Supply chain dependencies on raw materials expose to price volatility. Diversification efforts mitigate but do not eliminate this risk. Geopolitical tensions in Asia could disrupt expansion. Investors should track regional stability for international revenue projections. Consumer shifts toward natural products challenge synthetic formulas. Rohto's adaptation speed will determine competitive edge. Overall, Rohto Pharmaceutical stock presents a balanced opportunity. Its entrenched position supports long-term holding, with vigilance on global execution key. Disclaimer: Not investment advice. Stocks are volatile financial instruments. Rohto pharmaceutical-aktie: kaufen oder verkaufen?! Neue Rohto pharmaceutical-analyse vom 13. April liefert die antwort: Die neusten Rohto Pharmaceutical-Zahlen sprechen eine klare Sprache: Dringender Handlungsbedarf für Rohto Pharmaceutical-Aktionäre. Lohnt sich ein Einstieg oder sollten Sie lieber verkaufen? In der aktuellen Gratis-Analyse vom 13. April erfahren Sie was jetzt zu tun ist. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. en | JP3982400008 | ROHTO PHARMACEUTICAL CO LTD | boerse | 69062988 | bgmi

Santen Pharmaceutical
Mar 19th, 2026
Notice of Board of Director and Corporate auditor nominations.

Notice of Board of Director and Corporate auditor nominations. March 19, 2026, Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) at a Board of Directors meeting held March 19, 2026, resolved to propose the following candidates of the Board of Directors, which will be submitted for approval at the 114th Annual General Meeting of Shareholders and the Board of Directors to be held in June 2026. Please note that no changes to Corporate Auditors have been proposed. Members of the Board of Directors (After the 114th Annual General Meeting of Shareholders scheduled to be held in June 2026) [Directors] | / | Name | New position | Current position | | Reappointed | Takeshi Ito | Representative Director of the Board, President, Chief Executive Officer | Representative Director of the Board, President, Chief Executive Officer | | Rie Nakajima | Member of the Board, Corporate Officer Chief Operating Officer | Member of the Board, Corporate Officer Chief Operating Officer | | Ippei Kurihara | Member of the Board, Corporate Officer Head of Japan Business Global Commercial Strategy | Member of the Board, Corporate Officer Head of Japan Business Global Commercial Strategy | | Masahiko Ikaga | Member of the Board* | Member of the Board* | | Minoru Kikuoka | Member of the Board* | Member of the Board* | | Yukiko Kuroda | Member of the Board* | Member of the Board* | | Newly appointed | Tetsuya Uekusa | Member of the Board* | - | *Outside Directors and independent officers as designated by the Tokyo Stock Exchange About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" - Exploring the secrets and mechanisms of nature in order to contribute to people's health - Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit https://www.santen.com/en. Contact Corporate Communications Santen Pharmaceutical Co., Ltd. E-mail: [email protected]